Investor Relations FAQs on COVID-19
as of 04/09/2020

1. **How is the COVID-19 pandemic affecting Ocugen's manufacturing and supply chain?**
   Ocugen works with third-party partners to manufacture and supply the materials for our clinical trials. For our OCU300 clinical trial, all material has been manufactured and we are working with our suppliers and clinical trial sites to ship clinical supplies directly to patients if they are unable to make their regular visit.

   For our gene therapy program, the CanSinoBIO team, located in China, is back at work and continuing work on OCU400 manufacturing as it relates to our preclinical studies.

2. **Has COVID-19 impacted Ocugen's clinical trial?**
   Our Phase 3 study continued to enroll very well through mid-March. We shared in December that we had reached 50% of our planned enrollment and as of March 20th, we completed over 95% of our planned enrollment. We anticipate that we may experience a slowdown in the final stages of enrollment due to the coronavirus pandemic. Our clinical team is working closely with our sites to address the impact to our clinical trial.

   None of our sites are screening new subjects into the trial; however, because enrollment is so far ahead of schedule, we do not anticipate this pause in screening to impact the timing of our topline results.

   We are incorporating all four items recommended by the FDA in its recent Guidance on Conducting Clinical Trials during the COVID-19 Pandemic, which are: virtual visits, phone interviews, self-administration and remote monitoring. We have arranged for each patient's monthly supply of study medication to be shipped directly from the site to the patient rather than risking an in-person visit to pick up the medication. Fortunately, all patients can easily self-administer study medication and have been doing this since their very first visit. Our field monitors are working closely with site personnel to facilitate the process of remote monitoring. For those sites unable to conduct in-person follow-up visits, we are using virtual visits, which includes phone interviews, so we can continue the "safety checks" built into the protocol. We are also using the virtual visits to collect endpoint data.

   For those sites conducting in-person follow-up visits, they have a process in place to minimize risk to the patient. Additionally, the protocol has built-in windows around each assessment visit, so there is some flexibility as to the exact date of the follow-up visit, whether it is done remotely or in-person.

   As of right now, we still anticipate having topline results from this study before the end of the year.

3. **What is the impact of COVID-19 on Ocugen's ongoing operations (i.e. facilities, working from home)?**
   Ocugen fully supports measures to slow the spread of the virus and the safety of our employees is our top priority. We have shifted our workforce to work remotely.

Cautionary Note on Forward-Looking Statements

This FAQ contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding our business strategy, future results of operations and financial position, prospective products, product approvals, research and development costs, timing and likelihood of success, estimated market size or growth, and plans and objectives of management for future operations, are forward-looking statements. When used in this presentation, the words "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, including those risks set forth in the Company's filings with the Securities and Exchange Commission, which are available at www.sec.gov, that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information available to management as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

###